Home › Biliary Tract Cancer › Florida › Miami
Biliary Tract Cancer clinical trials in Miami, FL
5 studies for Biliary Tract Cancer are looking for participants at sites in and around Miami (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
- Research Site, Miami
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- University of Miami, Miami
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- University of Miami Hospital and Clinics, Miami
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RecruitingPhase 2
- Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics), Miami
Biliary Tract Cancer trials in other cities
- Houston, TX18 studies
- Los Angeles, CA11 studies
- Boston, MA11 studies
- New York City, NY10 studies
- Nashville, TN9 studies
- San Antonio, TX8 studies
- Baltimore, MD8 studies
- Washington, DC7 studies
- Arlington, VA7 studies
- Pittsburgh, PA7 studies
- Cleveland, OH6 studies
- Baldwin Park, CA6 studies
Other studies in Miami
- Breast Cancer42 studies
- Cancer (all types)36 studies
- Non-Small Cell Lung Cancer31 studies
- Prostate Cancer27 studies
- Obesity27 studies
- Acute Myeloid Leukemia24 studies
- Metastatic Cancer24 studies
- Ovarian Cancer23 studies
- Overweight23 studies
- Multiple Myeloma21 studies
- Ulcerative Colitis21 studies
- Alzheimer's Disease20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.